{"disease":{"id":"tardive-dyskinesia","name":"Tardive dyskinesia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"valbenazine","indication_name":"Tardive Dyskinesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ingrezza","generic_name":"valbenazine","company_name":"Neurocrine","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2, Synaptic vesicular amine transporter, Synaptic vesicular amine transporter","drug_class":"","quality_score":55,"revenue":"1900","mechanism":null},{"drug_id":"valbenazine","indication_name":"Tardive dyskinesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ingrezza","generic_name":"valbenazine","company_name":"Neurocrine","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2, Synaptic vesicular amine transporter, Synaptic vesicular amine transporter","drug_class":"","quality_score":55,"revenue":"1900","mechanism":null},{"drug_id":"deutetrabenazine","indication_name":"Tardive dyskinesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Austedo","generic_name":"DEUTETRABENAZINE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Synaptic vesicular amine transporter","drug_class":"","quality_score":70,"revenue":"1100","mechanism":"Austedo works by binding to the synaptic vesicular amine transporter, reducing the release of dopamine and other neurotransmitters."},{"drug_id":"deutetrabenazine","indication_name":"Tardive dyskinesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Austedo","generic_name":"DEUTETRABENAZINE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Synaptic vesicular amine transporter","drug_class":"","quality_score":70,"revenue":"1100","mechanism":"Austedo works by binding to the synaptic vesicular amine transporter, reducing the release of dopamine and other neurotransmitters."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02198794","title":"Reducing Involuntary Movements in Participants With Tardive Dyskinesia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":343,"lead_sponsor_name":"Auspex Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06011408","title":"Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes","phase":"NA","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"iRxReminder","has_results":false},{"nct_id":"NCT02291861","title":"Addressing Involuntary Movements in Tardive Dyskinesia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":298,"lead_sponsor_name":"Auspex Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03176771","title":"Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":256,"lead_sponsor_name":"Tanabe Pharma Corporation","has_results":true},{"nct_id":"NCT02736955","title":"Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":161,"lead_sponsor_name":"Neurocrine Biosciences","has_results":true},{"nct_id":"NCT03891862","title":"Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Neurocrine Biosciences","has_results":true},{"nct_id":"NCT06731868","title":"Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Luye Pharma Group Ltd.","has_results":false},{"nct_id":"NCT05238701","title":"A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"Luye Pharma Group Ltd.","has_results":false},{"nct_id":"NCT03698331","title":"The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Neurocrine Biosciences","has_results":true},{"nct_id":"NCT03497013","title":"Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia","phase":"NA","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Suzhou Psychiatric Hospital","has_results":false},{"nct_id":"NCT07173920","title":"Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localization) in Relieving Motor Symptoms of TD","phase":"NA","overall_status":"RECRUITING","enrollment_count":62,"lead_sponsor_name":"Peking University Sixth Hospital","has_results":false},{"nct_id":"NCT05859698","title":"Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Neurocrine Biosciences","has_results":true},{"nct_id":"NCT06216054","title":"Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Luye Pharma Group Ltd.","has_results":false},{"nct_id":"NCT06997198","title":"Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":25,"lead_sponsor_name":"University Hospitals Cleveland Medical Center","has_results":false},{"nct_id":"NCT03287778","title":"Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia","phase":"NA","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"University of North Carolina, Chapel Hill","has_results":false},{"nct_id":"NCT06474650","title":"Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Luye Pharma Group Ltd.","has_results":false},{"nct_id":"NCT03495024","title":"Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Corporal Michael J. Crescenz VA Medical Center","has_results":false},{"nct_id":"NCT04794413","title":"Pimavanserin Treatment in TS","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Joseph Jankovic","has_results":false},{"nct_id":"NCT03254186","title":"Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia","phase":"PHASE2, PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT05053321","title":"Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Yale University","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}